Common antidepressants increase antibiotic resistance

Dr Yue Wang and Professor Jianhua Guo

Researchers have found a range of commonly prescribed antidepressants can increase bacteria’s resistance to antibiotic medications.

A study led by Professor Jianhua Guo from University of Queensland’s Australian Centre for Water and Environmental Biotechnology focused on prescription drugs used to treat depressive disorders, anxiety disorders, and other psychological conditions. 

More than 42 million prescriptions were dispensed for antidepressant medications in Australia in 2021 and the study investigated bacterial exposure to five of the most common drugs – sertraline (Zoloft), escitalopram (Lexapro), bupropion (Welbutrin), duloxetine (Cymbalta) and agomelatine (Valdoxan).

“While the overuse of antibiotics is acknowledged as the major driver of bacterial resistance, we wanted to investigate if other common medications were contributing to the problem,” Professor Guo said. “Sertraline, duloxetine and fluoxetine had the strongest impact on bacterial resistance to antibiotics among the drugs we tested.

“Our study showed a marked increase in antibiotic resistance from those three, even at very low doses. Notably, the antibiotic resistance appears to be antidepressant-dependent, which may be due to oxidative stress in bacteria posed by antidepressants.”

It is estimated 1.27 million people die every year from infections which do not respond to medication and the figure is predicted to reach 10 million by 2050 unless global action is taken.

“Further studies need to evaluate the potential effects on the microbiomes of people given antidepressants and assess their risk gastrointestinal disturbances or diseases,” Professor Guo added.

The study is published in Proceedings of the National Academy of Sciences (PNAS) and was funded by the Australian Research Council Discovery Project, and the UQ Foundation Research Excellence Awards. 

Image shows: Dr Yue Wang (left) and Professor Jianhua Guo (right). 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free